Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,010,108 | 1,370,816 | 6,602,621 | 6,215,569 | 4,227,090 |
| Depreciation Amortization | 1,499,375 | 696,187 | 2,853,507 | 2,115,319 | 1,367,293 |
| Accounts receivable | N/A | N/A | -987,657 | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | -18,659 | N/A | N/A |
| Other Working Capital | -1,172,491 | -769,737 | -1,064,778 | -3,259,692 | -3,547,199 |
| Other Operating Activity | -723,183 | -82,426 | 1,033,680 | -549,401 | -344,328 |
| Operating Cash Flow | $2,613,809 | $1,214,840 | $8,418,715 | $4,521,795 | $1,702,856 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,866,229 | 1,342,918 | 2,215,386 | 998,795 | 939,075 |
| PPE Investments | -690,369 | -313,221 | -1,599,655 | -1,021,581 | -649,840 |
| Net Acquisitions | -960,458 | -915,568 | -1,750,167 | -1,776,058 | -1,679,066 |
| Sale Of Investment | N/A | N/A | N/A | 1,266 | 1,252 |
| Purchase Sale Intangibles | -538,917 | -365,213 | -1,266,290 | -912,714 | -654,848 |
| Other Investing Activity | -431,638 | -303,076 | -849,585 | -560,794 | -329,302 |
| Investing Cash Flow | $783,764 | $-188,947 | $-1,984,021 | $-2,358,372 | $-1,717,881 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -93,395 | N/A | -414,219 | 1,764,665 | 2,813,469 |
| Debt Issued | N/A | N/A | 277,390 | 301,284 | N/A |
| Debt Repayment | N/A | N/A | -179,122 | -182,290 | -187,815 |
| Common Stock Issued | 23,980 | 22,826 | 12,439 | 11,393 | 11,269 |
| Dividend Paid | -1,539,762 | -720,281 | -2,795,043 | -2,125,446 | -1,392,335 |
| Other Financing Activity | -1,727,815 | -646,731 | -3,918,285 | -2,363,436 | -1,603,941 |
| Financing Cash Flow | $-3,336,992 | $-1,344,186 | $-7,016,840 | $-2,593,829 | $-359,353 |
| Exchange Rate Effect | -34,077 | -24,094 | -123,146 | -82,284 | -110,185 |
| Beginning Cash Position | 3,607,082 | 3,624,230 | 4,260,357 | 4,335,708 | 4,288,442 |
| End Cash Position | 3,633,586 | 3,281,843 | 3,555,066 | 3,823,018 | 3,803,880 |
| Net Cash Flow | $26,504 | $-342,387 | $-705,291 | $-512,690 | $-484,563 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,613,809 | 1,214,840 | 8,418,715 | 4,521,795 | 1,702,856 |
| Capital Expenditure | -694,155 | -314,489 | -1,634,485 | -1,048,165 | -662,361 |
| Free Cash Flow | 1,919,654 | 900,351 | 6,784,230 | 3,473,630 | 1,040,495 |